The civic record
Read. Follow. Verify.Pennsylvania Bill SB 1481 regulates 340B drug reimbursement rates and prohibits discriminatory practices by insurers and manufacturers
Last action · September 25, 2026: Referred to HEALTH AND HUMAN SERVICES, Sept. 25, 2026Sponsors: Michele Brooks and 5 others
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
Pennsylvania Senate Bill 1481 prohibits pharmacy benefit managers, covered insurers, and drug manufacturers from discriminating against 340B covered entities and contract pharmacies by underpaying claims or restricting drug distribution. The measure sets minimum reimbursement rates based on national acquisition costs, requires exclusive use of claims-level billing modifiers, and establishes fines up to $50,000 per violation enforced by the Insurance Department and Office of Attorney General.
The measure directly alters payment terms and distribution rights for safety-net clinics, pharmacies, insurers, and drug manufacturers operating in Pennsylvania, establishing statutory fines and business suspension penalties for noncompliance.
- 340B drug pricing program requirements stem from federal legislation designed to allow safety-net healthcare providers to stretch scarce federal resources. context
- State legislation concerning pharmacy benefit managers and 340B reimbursement has expanded significantly across multiple states in recent years to address contract pharmacy restrictions. context
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
covered entities
Covered entities receive statutory protection regarding minimum reimbursement rates, grievance procedures, and non-discriminatory drug distribution.
contract pharmacies
Contract pharmacies are included in minimum reimbursement protections and are safeguarded against distance limitations and discriminatory pricing.
pharmacy benefit managers
Pharmacy benefit managers face prohibitions on underpaying 340B claims, mandated claims-level billing methodologies, and financial penalties for violations.
covered insurers
Covered insurers must comply with 340B reimbursement floors and are subject to audits, fines, and business suspension for noncompliance.
manufacturers
Manufacturers are prohibited from restricting or delaying 340B drug acquisitions and face fines up to $50,000 per violation.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
What reimbursement rates must insurers and pharmacy benefit managers pay for 340B drugs?
Which state agencies are responsible for enforcing the provisions of the Safety Net Nondiscrimination Act?
Can a covered entity waive its reimbursement protections under this act?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently in committee. The next step in the legislative lifecycle is Floor Vote.
Procedural history
1 action- Sep 25, 2026SenateCommitteeReferred to HEALTH AND HUMAN SERVICES, Sept. 25, 2026
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Show 1 more sponsor
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Comprehensive 340B Protection Framework
The bill pairs minimum reimbursement mandates for insurers with strict distribution protections and severe financial penalties for drug manufacturers.
Connected Entities
Sources
www.palegis.us
Analysis Score
0–100- Significance80How much this matters to a regular citizen
- Controversy65Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz40Current news / social attention level
Publisher tools